AbCellera Biologics Inc. ABCL Chief Executive

What Carl L.G. Hansen, Ph.D. says in public, and what their own SEC filings show they own.

Carl L.G. Hansen, Ph.D.

Carl L.G. Hansen, Ph.D.

Co-founder, President, Chief Executive Officer & Chairman · AbCellera Biologics Inc.

Ran the UBC lab the company was spun out of and has led it since its inception in November 2012; beneficially owns 65.2 million shares, 20.9% of the company, mostly through Thermopylae Holdings.

What they own

Ownership

Skin in the game
49/ 70
Level 4Founder-Anchor

Ph.D. owns about 19% of AbCellera Biologics Inc., worth $831.4M at the last close.

SEC filings
25
Stake 57.0M reported shares ≈ 18.6% of shares outstanding — no 13G on file, so an estimate 35/35
Founder Not assessed — whether they founded the company has not been researched Not assessed
Tenure No start date on record, so tenure scores nothing 0/10
Track record Not assessed — their prior companies have not been researched Not assessed
Direction No open-market buys or sales in the last year 5/15
Discipline 1 late Form 4 in 25 filings 9/10

Nobody has researched this person's career yet, so founder and track record are left out of the score and of the total above.

Score = stake band (35) + founder (15) + tenure (10) + track record (15) + 12-month direction (−10…15) + filing discipline (10). An axis we have not researched is left out of the score and of the total it is shown over. Every input links to a filing or to our own research; the bands are ours.

Reported · Forms 3, 4, 5 57.0M Every lot on the person's own filings, as of Nov 25, 2024
Paper trail 1 late filing Form 4 covering a 2022-02-22 option or RSU conversion in AbCellera Biologics Inc. was filed 2022-02-25, 3 business days later; Section 16 allows two.
Reported AbCellera Biologics Inc. shares Forms 3, 4 and 5 · as of 2024-11-25
020M40M60M 2021202220232024 57.0M
How the stake is held
SecurityHeld viaShares
Common SharesSee footnote56,086,009
Common SharesDirect898,000
Reported as of 2024-11-2556,984,009
Held directly
2%
Vehicles
1 trust or entity
Last filing
Jan 5, 2026
Every issuer Carl L.G. Hansen, Ph.D. files as an insider of
CompanyRoleReportedBeneficial% of class
ABCL AbCellera Biologics Inc. This page Chief Executive Officer 57M
2024-11-25		 — —

Reported is every lot on the person's own Forms 3, 4 and 5 — direct and through trusts. Beneficial is the figure stated on the latest Schedule 13D/G cover page, which can exclude shares the person disclaims and include options exercisable within 60 days, so the two are never added together.

Paper trail

25 filings under CIK 0001834412 · captured 2026-09-05 · All filings on EDGAR ↗

On the record with shareholders

Earnings calls

  1. Q2 2026 Aug 5, 2026 Carl Hansen used the call to argue that AbCellera has already stopped being a partnership business and is now a drug developer waiting on one number. He put the ABCL635 Phase 2 top-line readout — enrolled and dosed in June, ahead of schedule — at the centre of the year, stated in advance what he would count as success (a clean safety profile and roughly a 20% frequency response over placebo), and named the one thing that could still go wrong: whether blocking NK3R in the preoptic nucleus matters, which he said has never been proved pre-clinically and which the Phase 2 exists to answer. He also volunteered a missed timeline, on moving another program into IND-enabling work in the first half. Against that risk he set the T-cell engager platform, five years in the making, which had just produced Jazz and Vertex deals adding over $110 million of upfront cash and up to $4 billion of potential value — the argument being that the platform now funds the pipeline rather than competing with it. Read the call · 9 quotes →
In their own words

Podcasts, interviews & articles

3 recorded appearances

2026

Interview Investment Reports · Jun 11, 2026

Carl Hansen, AbCellera

Hansen explains why the company avoided venture capital until 2018 — a platform company on VC time gets pushed to an exit before it has built anything — and funded itself instead on partnership discovery revenue. Puts headcount at around 600 and frames the fully integrated biopharma ambition as a decades-long compounding exercise rather than a near-term goal.

Watch or read →

2025

Talk University of Austin (UATX) · Mar 12, 2025 · 1h 19m

Why medicines are miracles of science and technology | AbCellera CEO Carl Hansen

Hansen argues that biotech is at a watershed moment: scientific discovery is accelerating, but turning discoveries into medicines remains difficult and risky. He discusses the industry's hidden development bottlenecks, the technologies changing drug discovery, and his own path building AbCellera, followed by a live Q&A.

Watch or read →

Who else runs a company like this one

Every CEO we track →
David A. Ricks David A. Ricks Eli Lilly and Company (LLY) Joaquin Duato Joaquin Duato Johnson & Johnson (JNJ) Robert A. Michael AbbVie Inc. (ABBV) Stephen J. Hemsley Stephen J. Hemsley UnitedHealth Group Incorporated (UNH) Stéphane Bancel Stéphane Bancel Moderna, Inc. (MRNA)